Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Bronchiolitis Obliterans (BO): early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Bronchiolitis Obliterans (BO): 1 US clinical trial tracked, none currently recruiting.

Bronchiolitis Obliterans (BO) is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Hospital Medical Center, Cincinnati, running 1 of these trials.

Enrollment posture brief

Registry condition bronchiolitis-obliterans-bo

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Bronchiolitis Obliterans (this)Bronchiolitis Obliterans (th…0%
Open-enrollment share among volume-matched conditions near Bronchiolitis Obliterans (BO)

Bronchiolitis Obliterans (BO) has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Bronchiolitis Obliterans (BO) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Bronchiolitis Obliterans (BO) is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Bronchiolitis Obliterans (BO) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Ruxolitinib Drug
1 trials

US sites by state

Facility locations filed on Bronchiolitis Obliterans (BO) trials. A trial with sites in several states counts in each.

Ohio 1 trials
Minnesota 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Bronchiolitis Obliterans (BO) page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bronchiolitis Obliterans (BO) condition card totals 1 registered trials; most-linked intervention Ruxolitinib; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.